SCHEDULE 13G Filed 2026-06-05 Event — SEC 0001104659-26-071013 →

ADAR1 Capital Management, LLC → Rallybio Corporation RLYB

Stake: — Shares: — CUSIP: 75120L209 Class: Common Stock, par value $0.0001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 20/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (7.4 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

2 transactions

0 buys · 0 sales · 2 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

14 filings by this filer

13 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 7.39

40,962 shares short · -16.8% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

1 holder · $8.39M

Viking Global

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-09-24	Liu Hui	director	Option exercise	3,562	$2.38	$8K
2026-09-24	Liu Hui	director	Option exercise	8,482	$7.60	$64K

Other 13D/G Filings on Rallybio Corporation

Filed	Form	Filer	Stake	Shares
2024-01-02	SC	Novo Holdings A/S	—	—	view →
2022-01-18	SC	TPG GP A, LLC	—	—	view →

Other Filings by ADAR1 Capital Management, LLC

Filed	Form	Issuer	Stake	Shares
2026-09-08	SCHEDULE 13G	Tenax Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Cyclerion Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Rein Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Yarrow Bioscience, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	NextCure, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Editas Medicine, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	JATT II Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Amanat Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Boundless Bio, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Pliant Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Research Alliance Corporation III	—	—	view →
2026-06-05	SCHEDULE 13G	InMed Pharmaceuticals, Inc. INM	—	—	view →
2025-04-28	SCHEDULE	Keros Therapeutics, Inc. KROS	13.29%	5,390,964	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →